92e0ecf6cb51935c6389b20acb1d21ae57c0114f|Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Wei  Song, Deepthi  Pabbisetty, Elizabeth A Groeber, Rick C Steenwyk, Douglas M Fast|2009
fe6193f830a68ce6929eb542e8e4a48d3a1dcf93|Pharmacokinetics and Pharmacodynamics of Azosemide after Intravenous and Oral Administration to Rats with Alloxan‐induced Diabetes Mellitus|11a6591544db353811e93ffa61dd54fe0b3c52a4|K J Park, W H Yoon, W G Shin, M G Lee|1996
552bbb12c193d8b17baf81ec9448b14d5f18d0dc|A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia|379e2948292a4d417ba36dee19f77ca9ddbc9ad4|V S  Basile, V  Özdemir, M  Masellis, M L  Walker, H Y  Meltzer, J A  Lieberman, S G  Potkin, G  Alva, W  Kalow, F M  Macciardi, J L  Kennedy|2000
d2553b84ff891c6fc6296986dbe0cfefb59f8e9b|A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Kenjiro  Kosaki, Kazuyo  Tamura, Reiko  Sato, Hazuki  Samejima, Takao  Takahashi|2004
3dbe49c447e13673f6af17844b73de8a9fd042cb|EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).|b75ef2ac8493c7560e86686fa72046b446fd4613|W  Zhang, M  Doherty, N  Arden, B  Bannwarth, J  Bijlsma, K-P  Gunther, H J Hauselmann, G  Herrero-Beaumont, K  Jordan, P  Kaklamanis, B  Leeb, M  Lequesne, S  Lohmander, B  Mazieres, E  Martin-Mola, K  Pavelka, A  Pendleton, L  Punzi, B  Swoboda, R  Varatojo, G  Verbruggen, I  Zimmermann-Gorska, M  Dougados|2005
eb743fadfa3f40cd310989c192e4f23b4f77d512|Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS).|30b19862a9ed97d7a85f9b3d3c33a1214d0acab5|Michelle  Russell, Vitali  Pool, John M Kelso, Vesna J Tomazic-Jezic|2004
6234d502213da90529b22bf9c083d9bf32b4cbf9|Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.|c6e853ce2302282ee5651cf845d8a2f2d57547af|Charles M. Rudin, Wanqing  Liu, Apurva  Desai, Theodore  Karrison, Xuemin  Jiang, Linda  Janisch, Soma  Das, Jacqueline  Ramirez, Balasubramanian  Poonkuzhali, Erin  Schuetz, Donna Lee Fackenthal, Peixian  Chen, Deborah K. Armstrong, Julie R. Brahmer, Gini F. Fleming, Everett E. Vokes, Michael A. Carducci, Mark J. Ratain|2008
64e6c9853c00a82e61c2a6dab48361f8cf3d4706|Caffeine as a metabolic probe: Exploration of the enzyme‐inducing effect of cigarette smoking|552bbb12c193d8b17baf81ec9448b14d5f18d0dc|W  Kalow, B K Tang|1991
0b8712eab440ff4630d68344075424a815ad7f38|Glutathione S-Transferase Mu Modulates the Stress-activated Signals by Suppressing Apoptosis Signal-regulating Kinase 1*|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|S G Cho, Y H Lee, H S Park, K  Ryoo, K W Kang, J  Park, S J Eom, M J Kim, T S Chang, S Y Choi, J  Shim, Y  Kim, M S Dong, M J Lee, S G Kim, H  Ichijo, E J Choi|2001
99adc09c10cb74fcfb407777d496c51349febb88|Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.|ac7bb5263b7bbebbac633a535e65d815a84e458b|Lee S Rosen, Joseph  Brown, Bernadette  Laxa, Leny  Boulos, Laura  Reiswig, William D Henner, Robert T Lum, Steve R Schow, Christopher A Maack, James G Keck, Julie C Mascavage, Jacqueline A Dombroski, Reinaldo F Gomez, Gail L Brown|2003
27fa6ba5e7c5e0d961230f40e01734983e2bfcf1|Tumor-specific expression of cytochrome P450 CYP1B1.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|G I Murray, M C Taylor, M C McFadyen, J A McKay, W F Greenlee, M D Burke, W T Melvin|1997
30b19862a9ed97d7a85f9b3d3c33a1214d0acab5|General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).|b75ef2ac8493c7560e86686fa72046b446fd4613|Andrew T Kroger, William L Atkinson, Edgar K Marcuse, Larry K Pickering|2006
17c9deab8cdc504821f6983d9842035944c0590b|Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|K S Fenner, M D Troutman, S  Kempshall, J A Cook, J A Ware, D A Smith, C A Lee|2009
a35d000666502fc66710ce172b51bdb07f83f572|The relative toxicity of disease-modifying antirheumatic drugs.|b75ef2ac8493c7560e86686fa72046b446fd4613|J F Fries, C A Williams, D  Ramey, D A Bloch|1993
ac7bb5263b7bbebbac633a535e65d815a84e458b|Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Victoria J Findlay, Danyelle M Townsend, Joseph E Saavedra, Gregory S Buzard, Michael L Citro, Larry K Keefer, Xinhua  Ji, Kenneth D Tew|2004
f09c4a8f4459db34bb872b29f6ef9c4a60afc24b|Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Kari  Laine, Gunnel  Tybring, Sebastian  Härtter, Katarina  Andersson RN, Jan‐Olof  Svensson, Jolanta  Widén, Leif  Bertilsson|2001
5c757eff5aa3020ae22daf760fe3e40b8206e9b1|Genetic control of the innate immune response|4e507c871f6584fc085ce60b8a28cbb4c301da04|Christine A Wells, Timothy  Ravasi, Geoffrey J Faulkner, Piero  Carninci, Yasushi  Okazaki, Yoshihide  Hayashizaki, Matthew  Sweet, Brandon J Wainwright, David A Hume|2003
b75ef2ac8493c7560e86686fa72046b446fd4613|American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.|43f1d9dfff9455591a9f5943e90849855ddf5be7|Kenneth G Saag, Gim Gee Teng, Nivedita M Patkar, Jeremy  Anuntiyo, Catherine  Finney, Jeffrey R Curtis, Harold E Paulus, Amy  Mudano, Maria  Pisu, Mary  Elkins-Melton, Ryan  Outman, Jeroan J Allison, Maria  Suarez Almazor, S Louis Bridges, W Winn Chatham, Marc  Hochberg, Catherine  MacLean, Ted  Mikuls, Larry W Moreland, James  O'Dell, Anthony M Turkiewicz, Daniel E Furst|2008
95306331cc4aa4ba115c45e95c04a0bd7d3518c6|Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid.|b75ef2ac8493c7560e86686fa72046b446fd4613|L  Ambrosius Christensen, S N Rasmussen, S H Hansen, S  Bondesen, E F Hvidberg|1987
9b81bd44d5228341f47c050489a7b01344aaa46a|Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.|b75ef2ac8493c7560e86686fa72046b446fd4613|Joel M Kremer, Michael E Weinblatt, Arthur D Bankhurst, Ken J Bulpitt, Roy M Fleischmann, Christopher G Jackson, Kelly M Atkins, Anyang  Feng, Daniel J Burge|2003
c5d4a56637c0ce685730e1c73285f20fc6755218|Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Steven T Okino, Deepa  Pookot, Long-Cheng  Li, Hong  Zhao, Shinji  Urakami, Hiroaki  Shiina, Mikio  Igawa, Rajvir  Dahiya|2006
a6066516c7417b595edc9d6077b9ac6b138f3af3|Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).|c6e853ce2302282ee5651cf845d8a2f2d57547af|Katrin  Letschert, Dietrich  Keppler, Jörg  König|2004
67f86388466b838b36f2935b306ace393d092c8a|Comparison between the efficiencies of columns packed with fully and partially porous C18-bonded silica materials.|92e0ecf6cb51935c6389b20acb1d21ae57c0114f|Fabrice  Gritti, Alberto  Cavazzini, Nicola  Marchetti, Georges  Guiochon|2007
4e507c871f6584fc085ce60b8a28cbb4c301da04|Bacterial- and Viral-Induced Inflammation Increases Sensitivity to Acetaminophen Hepatotoxicity|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Jane F. Maddox, Chidozie J. Amuzie, Maoxiang  Li, Sandra W. Newport, Erica M. Sparkenbaugh, Christopher F. Cuff, James J. Pestka, Glenn H. Cantor, Robert A. Roth, Patricia E. Ganey|2010
11a6591544db353811e93ffa61dd54fe0b3c52a4|Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan‐induced diabetes mellitus|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|J H Park, W I Lee, W H Yoon, Y D Park, J S Lee, M G Lee|1998
985886e087e5b95b8fe52b34eb153249265c56ef|Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|S  Chakraborty, S  Kanakasabai, J J Bright|2011
c6e853ce2302282ee5651cf845d8a2f2d57547af|Drug transporters in drug efficacy and toxicity.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|M.K.  DeGorter, C.Q.  Xia, J.J.  Yang, R.B.  Kim|2012
2c55e816a70d3a1f21cb8d4a5812cc91f3400fb0|NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|John D. Hayes, Michael  McMahon|2009
b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Topics on Drug Metabolism|-|James  Paxton|2012
379e2948292a4d417ba36dee19f77ca9ddbc9ad4|Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Eleni  Aklillu, Juan Antonio Carrillo, Eyasu  Makonnen, Karin  Hellman, Marià  Pitarque, Leif  Bertilsson, Magnus  Ingelman-Sundberg|2003
ef4ea110f0ce3d0355abbc0c6c71782f93833626|A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.|6234d502213da90529b22bf9c083d9bf32b4cbf9|T  Moriai, M S Kobrin, C  Hope, L  Speck, M  Korc|1994
915804735311d80e34eca00b051a1cfd676f61cf|Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Shu-Feng  Zhou, Zhi-Wei  Zhou, Li-Ping  Yang, Jian-Ping  Cai|2009
2fb2bc093a6f5e11716d39219029c80a0703c30b|In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Lawrence H Cohen, Michael J Remley, David  Raunig, Alfin D N Vaz|2003
8c89a126905fbea4c36a53add600625338202cc8|Thiomersal allergy and vaccination reactions|30b19862a9ed97d7a85f9b3d3c33a1214d0acab5|N H Cox, A  Forsyth|1988
fa0df33368321e0fbdfddc2b1beee524ebd81b8c|Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.|43f1d9dfff9455591a9f5943e90849855ddf5be7|Marianne G. Rots, Rob  Pieters, Godefridus J. Peters, Paul  Noordhuis, Christina H. van Zantwijk, Gertjan J. L. Kaspers, Karel  Hählen, Ursula  Creutzig, Anjo J. P. Veerman, Gerrit  Jansen|1999
43f1d9dfff9455591a9f5943e90849855ddf5be7|[The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 1)].|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|Jerzy  Swierkot, Ryszard  Slęzak|2011
a04ca6a8d12278f8983c236b18412c2a6a2a12b3|Mechanisms of cytochrome P450 substrate oxidation: MiniReview|b8eab1d6f9b597de4b8bee8b69c819aa1818bdcf|F Peter Guengerich|2007
f0ef483bb297e02fd2066dceea54e3fe8fa64b8a|Neutrophil depletion protects against murine acetaminophen hepatotoxicity|4e507c871f6584fc085ce60b8a28cbb4c301da04|Zhang-Xu  Liu, Derick  Han, Basuki  Gunawan, Neil  Kaplowitz|2006
ca85b31a3d3a9584e89a49e3b3db0cd93d424208|Tumor necrosis factor inhibitors for rheumatoid arthritis.|b75ef2ac8493c7560e86686fa72046b446fd4613|D L Scott, G H Kingsley|2006
dcbecf34d54f9a2054b550128d2fa262df6a70e4|Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study.|3dbe49c447e13673f6af17844b73de8a9fd042cb|Yuqing  Zhang, Jingbo  Niu, Margaret  Kelly-Hayes, Christine E Chaisson, Piran  Aliabadi, David T Felson|2002
9260b574d775ab11ea243ab8bf314f5c1368601e|Clinical, radiologic, demographic, and occupational aspects of hand osteoarthritis in the elderly.|3dbe49c447e13673f6af17844b73de8a9fd042cb|D  Caspi, G  Flusser, I  Farber, J  Ribak, A  Leibovitz, B  Habot, M  Yaron, R  Segal|2001
